Effectiveness of Renal Denervation Therapy for Resistant Hypertension A Systematic Review and Meta-Analysis by Davis, Mark I. et al.
Journal of the American College of Cardiology Vol. 62, No. 3, 2013
 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.04.010HypertensionEffectiveness of Renal Denervation Therapy
for Resistant Hypertension
A Systematic Review and Meta-Analysis
Mark I. Davis, MD,* Kristian B. Filion, PHD,y David Zhang,* Mark J. Eisenberg, MD, MPH,*z
Jonathan Aﬁlalo, MD, MSC,*z Ernesto L. Schiffrin, MD, PHD,*x Dominique Joyal, MD*z
Montreal, CanadaFrom the *
University, M
Hospital, M
General Ho
Institute for
treal, Canad
contents of
Manuscri
accepted ApObjectives TDepartment of Internal
ontreal, Canada; yDivis
cGill University, Montr
spital, McGill Universit
Medical Research, Jewis
a. The authors have report
this paper to disclose.
pt received January 10, 201
ril 7, 2013.his study sought to determine the current effectiveness and safety of sympathetic renal denervation (RDN) for
resistant hypertension.Background RDN is a novel approach that has been evaluated in multiple small studies.Methods We performed a systematic review and meta-analysis of published studies evaluating the effect of RDN in patients
with resistant hypertension. Studies were stratiﬁed according to controlled versus uncontrolled design and analyzed
using random-effects meta-analysis models.Results We identiﬁed 2 randomized controlled trials, 1 observational study with a control group, and 9 observational studies
without a control group. In controlled studies, there was a reduction in mean systolic and diastolic blood pressure (BP)
at 6 months of –28.9 mm Hg (95% conﬁdence interval [CI]: –37.2 to –20.6 mm Hg) and –11.0 mm Hg (95% CI:
–16.4 to –5.7 mm Hg), respectively, compared with medically treated patients (for both, p < 0.0001). In uncontrolled
studies, there was a reduction in mean systolic and diastolic BP at 6 months of –25.0 mm Hg (95% CI: –29.9 to –20.1
mm Hg) and –10.0 mm Hg (95% CI: –12.5 to –7.5 mm Hg), respectively, compared with pre-RDN values (for both,
p < 0.00001). There was no difference in the effect of RDN according to the 5 catheters employed. Reported
procedural complications included 1 renal artery dissection and 4 femoral pseudoaneurysms.Conclusions RDN resulted in a substantial reduction in mean BP at 6 months in patients with resistant hypertension. The
decrease in BP was similar irrespective of study design and type of catheter employed. Large randomized controlled
trials with long-term follow-up are needed to conﬁrm the sustained efﬁcacy and safety of RDN. (J Am Coll Cardiol
2013;62:231–41) ª 2013 by the American College of Cardiology FoundationResistant hypertension (RH) is deﬁned as uncontrolled
systolic blood pressures (BP) despite therapy with 3 anti-
hypertensive agents from at least 3 different classes including
a diuretic. In most studies, 10% to 15% of hypertensive
subjects (1,2), but up to 20% of the hypertensive population
in some publications (3), have RH, particularly those with
advanced age, obesity, diabetes mellitus, sleep apnea, and
chronic kidney disease (4–6). In patients with RH, phar-
macological options are limited. Historically, a surgical
option, namely sympathectomy, led to a signiﬁcant reduc-
tion in BP but was associated with high surgical morbidityMedicine, Jewish General Hospital, McGill
ion of Clinical Epidemiology, Jewish General
eal, Canada; zDivision of Cardiology, Jewish
y, Montreal, Canada; and the xLady Davis
h General Hospital, McGill University, Mon-
ed that they have no relationships relevant to the
3; revised manuscript received March 18, 2013,(7–9). Although surgical sympathectomy was largely aban-
doned in clinical practice, there has been a renewed interest
in the concept as animal models (10,11) have shown that
renal sympathectomy leads to signiﬁcant reduction in BP
and improvement in end organ function (12–15).
Percutaneous renal sympathectomy has emerged as a safer,
although invasive approach using radiofrequency probes to
ablate the sympathetic ﬁbers along the renal artery. The
proof of concept study (16) demonstrated surprisingly good
results and was subsequently followed by a series of studies
using different catheters. These studies have generated great
enthusiasm such that percutaneous renal denervation therapy
(RDN) has been adopted at a rate rarely seen in the hyper-
tension ﬁeld. RDN for RH is currently approved in Europe
and Canada and is pending approval in the United States.
One RDN catheter system (Medtronic Ardian Inc., Palo
Alto, California) has been used to treat over 4,000 patients
worldwide thus far (17). Despite the enthusiasm and rapid
uptake, there has yet to be a comprehensive review of the
available evidence to support the practice of RDN.
Abbreviations
and Acronyms
BP = blood pressure
CI = conﬁdence interval
DBP = diastolic blood
pressure
RDN = renal sympathetic
denervation
RH = resistant hypertension
SBP = systolic blood
pressure
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232We have systematically re-
viewed the current body of evi-
dence for RDN and quantiﬁed
its BP-lowering effect in patients
with RH using a random effects
meta-analysis model.Methods
Data sources and search
strategy. We performed a sys-
tematic review and meta-analysis
in accordance with the standardsset forth by the PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) statement (18,19).
We searched PubMed, EMBASE, and the Cochrane
Collaboration database using the key words “renal dener-
vation,” “blood pressure,” and “hypertension.” The search
was limited to English language articles published in the last
5 years (this technology was only developed in that time
frame). In addition, we hand-searched references of retrieved
articles and used PubMed’s related articles feature to identify
studies not captured by our primary search strategy. The
ﬁnal search was run on December 1, 2012.
Study selection. We included randomized and observa-
tional studies comparing BP response in patients treated with
RDN versus patients treated with standard medical therapy
(controlled studies) and observational studies comparing
BP in a single group of patients before and after RDN
(uncontrolled studies). Inclusion criteria were: 1) RDN per-
formed using contemporary percutaneous catheters and
radiofrequency probes; 2) patient population with RH (not
meeting BP target despite therapy with 3 or more antihy-
pertensive agents from at least 3 different classes); 3) at least
10 study participants; and 4) at least 3 months of follow-up
for BP response. BP measurements could include manual,
automated, or invasive BP recordings, as long as the same
method was used before and after RDN. Reviews, editorials,
letters, animal studies, case reports, and conference abstracts
were excluded. Once full articles were retrieved, studies were
further excluded if there was an overlap in patients with
another study within the same analysis (in which case, the
larger sample size of the 2 studies was selected). Thus, whereas
some patients could possibly have been included in both
the controlled and uncontrolled study analyses, they were
only included once in any given analysis. Consequently, there
was no overlap in patients included in our meta-analyses.
Data extraction. Data was extracted in duplicate by 2 inde-
pendent reviewers (M.D., D.Z.). Disagreements were resolved
by consensus. We extracted data pertaining to baseline char-
acteristics of study subjects (number of subjects, age, sex,
comorbidities, antihypertensive agents), trial inclusion and
exclusion criteria, method of BPmeasurement, type of catheter
used, BP response to RDN (including BP before and after
RDN), nonresponder rate, procedural complications, maximal
length of follow-up, and mortality.Outcomes. The primary outcome measure was mean
systolic and diastolic BP reduction following RDN between
3 and 6 months of follow-up. Secondary outcome measures
included: 1) nonresponder rate, deﬁned as an achieved
decrease in systolic BP of <10 mm Hg; 2) mean BP
reduction stratiﬁed by catheter type; and 3) reported
procedural complications and averse outcomes including
death from any cause.
Methodological quality. To determine the quality of the
included studies, we used the Cochrane Collaboration Risk of
Bias Tool (Online Appendix 1) for the 2 randomized control
trials and the Newcastle-Ottawa scale for the observational
studies. We set a follow-up rate of >70% at 6 months as
a limit to determine high risks of bias at follow-up for studies
evaluated with the Newcastle-Ottawa scale in the outcome
section of this scale (Online Appendix 2).
Data synthesis and statistical analysis. For controlled stud-
ies, the difference in BP change with RDN versus medical
therapy was pooled across studies and analyzed using
random-effects meta-analysis models with inverse variance
weighting. Separate models were constructed for 3 and
6 months of follow-up. For uncontrolled studies, the BP
change before versus after RDN was pooled and analyzed
using the same meta-analysis models. The magnitude of
heterogeneity present was estimated using the I2 statistic,
an estimate of the proportion of the total observed variance
that is attributed to between-study variance. To compare
the magnitude of BP reduction based on the type of
RDN catheter used, we constructed a separate meta-analysis
stratiﬁed by catheter type using a random-effects generic
inverse variance-weighting model to compare heterogeneity
using the I2 statistic.
Certain studies reported measures of variability other than
SD. In these cases, 95% conﬁdence intervals or standard error
of the mean were converted to SD to maintain consistency
of the reported results. In a study by Witkowski et al. (20),
the only measure of variability reported was interquartile
range. By including this study in the meta-analysis models,
we are assuming a normal distribution of change in BP. In the
study by Prochnau et al. (21), no estimate of variance was
reported, thus we assumed a SD equal to the mean of other
reported SD. Sensitivity analyses were performed excluding
these 2 studies. We considered p < 0.05 signiﬁcant.
Throughout, values are presented as mean  SD unless
otherwise stated. Analyses were performed using the
Cochrane Collaboration Review Manager (version 5.1.7,
Cochrane Collaboration, Copenhagen, Denmark) and the
GraphPad Prism (version 6.0, GraphPad Software, La Jolla,
California) software packages.Results
Study selection and characteristics. Our literature search
identiﬁed 294 potentially relevant studies as shown in the
ﬂow diagram (Fig. 1). Of these, 18 studies met the inclusion
criteria. Six additional studies were excluded due to overlap
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233of patients (22–27). All six of these studies were con-
trolled studies with overlap of patients with the Symplicity
HTN-2 (Renal Sympathetic Denervation in Patients With
Treatment-Resistant Hypertension) study and could not be
included in the controlled study meta-analysis. On the other
hand, the Ukena et al. study (28), which is an uncontrolled
study, is included in the uncontrolled study meta-analysis
even though 18 (of 136) patients overlap with Symplicity
HTN-2, because these 2 studies are included in separate
meta-analyses. Thus, 12 studies were included in our sys-
tematic review, encompassing 561 patients treated between
2008 and 2012. The 12-month follow-up data for a study
was published in a separate article and the follow-up data was
extracted (29,30). The follow-up duration varied between
1 and 24 months with a median follow-up of 6 months.
Table 1 summarizes the design and methods of the
included studies. There were 2 randomized controlled trials
(n ¼ 133) and 1 observational study with a control group
(n ¼ 50) (i.e., controlled studies), and 9 observational
studies without a control group (n ¼ 396) (i.e., uncontrolled
studies). The inclusion and exclusion criteria were in largeFigure 1 Flow Diagram for Study Selection
Studies were selected by a 3-stage exclusion process. Studies were ﬁrst screened based
based on number of participants and length of follow-up. Finally, 6 further studies were epart similar, although 1 study included patients at the lower
end of the RH spectrum (31), and another study included
only patients with moderate to severe chronic kidney disease
(32). Ambulatory BP monitors were employed to measure
the primary outcome of BP response (and used for the meta-
analysis) in 2 studies (21,33), with these measurements
being relatively lower than ofﬁce measurements, which were
used as the primary outcome measure (and used for the
meta-analysis) in the other 10 studies (16,20,28,30–32,
34–37). The risk of bias was low in the majority of
studies, with a detailed assessment available in Online
Appendixes 1 and 2.
Tables 2 and 3 summarize the patient characteristics and
concomitant therapies, respectively. Sixty percent of patients
were male and the average age was 60 years. Thirty-ﬁve
percent of patients had type 2 diabetes mellitus and 18%
had coronary artery disease. Patients with RH were receiving
an average of 5 different antihypertensive medications.
Effectiveness of RDN. In controlled studies, there was
a reduction in mean systolic and diastolic BP at 6 months
of –28.9 mm Hg (95% conﬁdence interval [CI]: –37.2 toon abstract. Following selection of appropriate studies, studies were excluded
xcluded due to an overlap in patient populations.
Table 1 Characteristics and Inclusion Criteria of All Included Studies
Study/
First Author
(Ref. #) Year Type of Study
Method of BP
Measurement
for Analysis Inclusion/Exclusion Criteria Type of Catheter
RDN
Patients,
n
Control
Patients,
n
Length of
Follow-Up,
Months
Nonresponder
Rate,
%
Randomized control trials
Pokushalov
et al. (36)
2012 Randomized
control
trial
Ofﬁce BP in
triplicate
Inclusion: Symptomatic drug refractory AF on 2
antiarrhythmics; paroxysmal AF; standard criteria* but no
exception to valvular disease, ICD/pacemaker, or medication
changes;
Exclusion: no NYHA class III or IV CHF; no LVEF <35%;
no previous AF ablation; no treatment with amiodarone
Navistar ThermoCool
catheter (Biosense
Webster)
13 14 3, 6, 9, 12 0
Symplicity
HTN-2
(29,30)yz
2010,
2012
Randomized
control
trial
Ofﬁce BP in
triplicate
Standard criteria* Symplicity (Ardian,
Medtronic)
52 54 1, 3, 6, 12 16
Observational control study
Krum et al.
(16)
2009 Prospective
cohort
Ofﬁce BP in
triplicate
Standard criteria* Symplicity (Ardian,
Medtronic)
45 5 1, 3, 6, 9, 12 13
Observational studies
Ahmed
et al.
(33)
2012 Prospective
cohort
24-h AMBP Standard criteria* except SBP 140 mm Hg and no exception to
valvular disease, ICD/pacemaker, or medication changes
Celsius ThermoCool
catheter (Biosense
Webster)
10 N/A 1, 3, 6 0
Hering et al.
(32)
2012 Prospective
cohort
Ofﬁce BP in
triplicate
Inclusion: patients with stage 3–4 chronic kidney disease and
resistant HTN
Symplicity (Ardian,
Medtronic)
15 N/A 1, 3, 6, 12 NR
Kaltenbach
et al. (31)
2012 Prospective
cohort
Ofﬁce BP in
triplicate
Inclusion: SBP 140–160 mm Hg; 3 antihypertensives;
Exclusion: no secondary causes of HTN
Symplicity (Ardian,
Medtronic)
20 N/A 3, 6 45
Mabin et al.
(35)
2012 Prospective
cohort
Ofﬁce BP in
triplicate
Standard criteria* but BP 140/90 mm Hg and no exclusion of
valvular disease, ICD/pacemaker, or medication changes
PARADISE
Ultrasound
catheter (ReCor
Medical)
11 N/A 0.5, 1, 2, 3 NR
Prochnau
et al. (21)
2012 Prospective
cohort
24-h ABPM Inclusion: mean 24-h ambulatory SBP 150 mm Hg,
4 antihypertensives
Exclusion: no secondary causes of HTN; no known RVA
Marinr standard
steerable RF
ablation catheter
(Medtronic)
30 N/A 1, 3, 6, 12 NR (25 in
initial
study)
Symplicity
HTN-1
(34)
2011 Prospective
cohort
Ofﬁce BP in
triplicate
Standard criteria* except no exception to medication changes Symplicity (Ardian,
Medtronic)
153 N/A 1, 3, 6,
12, 18, 24
8
Ukena et al.
(28)z
2012 Prospective
cohort
Ofﬁce BP in
triplicate
Standard criteria* except no medication changes within 2 weeks
of study enrollment
Flex (Medtronic) 136 N/A 3, 6 17
Witkowski
et al. (20)
2011 Prospective
cohort
Ofﬁce BP in
triplicate
Standard criteria* except no medication changes within 2 weeks
of study enrollment; diagnosed sleep apnea
Symplicity (Ardian,
Medtronic)
10 N/A 3, 6 0
Zuern et al.
(37)
2012 Prospective
cohort
Ofﬁce BP in
triplicate
Standard criteria* except no medication changes within 2 weeks
of study enrollment
Flex (Ardian,
Medtronic)
11 N/A 6 18
*Standard criteria: these are the initial inclusion and exclusion criteria of the original RDN trial by Krum: age18 years; SBP 160 mm Hg (150 mm Hg if type 2 diabetes mellitus); 3 antihypertensives (including a diuretic); eGFR >45 ml/min/1.73 m2; no secondary causes
of HTN; no type 1 diabetes mellitus; no known renovascular abnormalities; no valvular disease; no ICD/pacemaker; not pregnant; no medication changes within 3 months of study enrollment. yIncludes the 12-month follow-up data of the same clinical cohort. zThere exists an
overlap of 18 patients between these studies.
ABPM ¼ ambulatory blood pressure monitoring; AF ¼ atrial ﬁbrillation; BP ¼ blood pressure; CHF ¼ congestive heart failure; eGFR ¼ estimated glomerular ﬁltration rate; HTN ¼ hypertension; ICD ¼ implantable cardiac deﬁbrillator; LVEF ¼ left ventricular ejection
fraction; N/A ¼ not available; NR ¼ not reported; NYHA ¼ New York Heart Association; RDN ¼ renal sympathetic denervation; RF ¼ radiofrequency; RVA ¼ renovascular abnormalities; SBP ¼ systolic blood pressure; Symplicity HTN-1 ¼ catheter-based renal sympathetic
denervation for resistant hypertension: durability of blood pressure reduction out to 24 months; Symplicity HTN-2 ¼ Renal Sympathetic Denervation in Patients With Treatment-Resistant Hypertension study.
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Table 2 Baseline Characteristics of the Included Study Subjects
Study/First Author (Ref. #) Treatment Group
Age,
yrs
Male,
%
Heart Rate,
beats/min
GFR,
ml/min/1.73 m2
BMI,
kg/m2
T2DM,
%
CAD,
%
Dyslipidemia,
%
Baseline BP,
mm Hg
Randomized control trials
Pokushalov et al. (36) RDN 57  8 79 NR 78  6 28  6 8 15 23 181  7/97  6
Medical therapy 56  9 71 NR 80.2  5.0 28  5 14 14 21 178  8/96  4
Symplicity HTN-2 (30)* RDN 58  12 65 75  15 77  19 31  5 40 19 52 178  18/97  16
Medical therapy 58  12 50 71  15 86  20 31  5 28 7 52 178  16/98  17
Observational control study
Krum et al. (16) RDN 58  9 56 72  11 81  23 NR 31 22 64 177  20/101  15
Medical therapy 51  8 80 79  9 95  15 NR 40 20 100 173  8/98  9
Observational studies
Ahmed et al. (33) RDN 61  12 80 NR NR 33  5 30 20 60 158  16/88  15
Hering et al. (32) RDN 61  9 60 64  9 31  9 NR 73 NR NR 174  22/91  16
Kaltenbach et al. (31) RDN 61  11 55 NR 77  25 NR 50 50 NR 148  7/83  11
Mabin et al. (35) RDN 55  14 36 NR NR NR 27 36 64 180  20/109  13
Prochnau et al. (21) RDN 62  13 67 NR NR NR 50 20 NR 166  22/88  13
Symplicity HTN-1 (34) RDN 57  11 61 73  13 83  20 NR 31 22 68 176  17/98  15
Ukena et al. (28)* RDN 62  9 58 66  12 NR 31  5 39 10 NR 177  21/93  15
Witkowski et al. (20) RDN 50  12 70 NR 81  11 32  7 40 NR NR 174  9/103  12
Zuern et al. (37) RDN 69  7 73 NR 75  18 29  3 36 36 36 189  23/92  15
Values are mean  SD or %. *There exists an overlap of 18 patients between these studies.
CAD ¼ coronary artery disease; GFR ¼ glomerular ﬁltration rate; T2DM ¼ type 2 diabetes mellitus; other abbreviations as in Table 1.
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Table 3 Baseline Antihypertensive Usage of the Included Studies
Study/First Author (Ref. #) Treatment Group
Antihypertensives,
n ACEI/ARB, %
Direct Renin
Inhibitor, %
Beta-
Blocker, %
CCB,
%
Diuretic,
%
Central
Sympatholytic, %
Vasodilator,
%
Alpha 1-
Blocker, %
Randomized control trials
Pokushalov et al. (36) RDN 3.8  0.4 92 NR 77 76 100 NR NR NR
Medical therapy 3.6  0.6 100 NR 78 71 92 NR NR NR
Symplicity HTN-2 (30)* RDN 5.2  1.5 96 15 83 79 89 52 15 33
Medical therapy 5.3  1.8 94 19 69 83 91 52 17 19
Observational control study
Krum et al. (16) RDN 4.7  1.5 96 NR 76 69 96 NR 18 NR
Medical therapy 4.6  0.5 80 NR 100 100 60 NR 0 NR
Observational studies
Ahmed et al. (33) RDN 6.7  1.0 100 NR 80 90 100 100 NR NR
Hering et al. (32) RDN 5.6  1.3 100 29 73 80 100 47 27 27
Kaltenbach et al. (31) RDN 5.4  1.5 100 45 90 80 85 60 15 40
Mabin et al. (35) RDN 4.5 82–100 NR 36 91 100 NR 9 27
Prochnau et al. (21)y RDN 6 97 87 77 97 73 33 43
Symplicity HTN-1 (34) RDN 5.1  1.4 91 14 82 75 95 33 19 19
Ukena et al. (28)* RDN 5.5  1.2 86 NR 88 72 100 46 NR NR
Witkowski et al. (20) RDN 5.0  0.9 100 NR 100 80 100 20 NR 20
Zuern et al. (37) RDN 5.6  2.1 100 55 73 82 100 73 18 36
Values are mean  SD or %. *There exists an overlap of 18 patients between these studies. yThe Prochnau et al. (22) study grouped patients with ACEI, ARB, and direct renin inhibitor together.
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin II receptor blocker; CCB ¼ calcium channel blocker; other abbreviations as in Table 1.
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237–20.6 mm Hg) and –11.0 mm Hg (95% CI: –16.4 to –5.7
mm Hg), respectively, with RDN versus medical therapy
(for both, p < 0.0001) (Fig. 2). At 3 months, there were
reductions of –20.8 mmHg systolic (95% CI: –26.4 to –15.2
mm Hg) and –7.6 mm Hg diastolic BP (95% CI: –11.0 to
–4.2 mm Hg). At 12 months, there were reductions of –25.4
mmHg systolic (95% CI: –27.8 to –23.0 mmHg) and –10.0
mmHg diastolic (95% CI: –11.0 to –9.0 mmHg). There was
a modest amount of heterogeneity (I2 ¼ 0 at 3 months and
50% to 60% at 6 months) between these studies.
In uncontrolled studies, there was a reduction in mean
systolic and diastolic BP at 6 months of –25.0 mm Hg (95%
CI: –29.9 to –20.1 mm Hg) and –10.0 mm Hg (95% CI:
–12.5 to –7.5 mm Hg), respectively, before compared with
after RDN (for both, p < 0.00001) (Fig. 3). At 3 months,
there were reductions of –22.8 mm Hg systolic blood
pressure (SBP) (95% CI: –26.3 to –18.5 mm Hg) and –9.1
mm Hg diastolic blood pressure (DBP) (95% CI: –12.1 to
–6.1 mm Hg). At 12 months, there were reductions of –22.8
mm Hg SBP (95% CI: –29.6 to –16.0) and –10.6 mm Hg
DBP (95% CI: –15.0 to –6.0 mm Hg). There was a signif-
icant amount of heterogeneity at the 3-month (I2 ¼ 66%
and 80% for SBP and DBP, respectively) and 6-month (I2¼
70% and 50% for SBP and DBP, respectively) time points.
However, sensitivity analysis excluding the Kaltenbach studyFigure 2 Meta-Analysis of Controlled Studies
Forest plot demonstrating the changes in systolic and diastolic blood pressures (BP) stra
denervation (RDN). CI ¼ conﬁdence interval(s); IV ¼ inverse variance; Symplicity HTN-2 ¼
study.(which included patients with lower baseline BP) indicated
that the heterogeneity was no longer apparent (I2 ¼ 0),
whereas the BP change was maintained (–24/–10 and
–27/–11 mm Hg at 3 and 6 months, respectively). Only
6 studies (21,30–33,37) had adequate 6-month follow-up of
ambulatory BP following RDN. The overall BP response
was smaller than that seen in studies solely evaluating ofﬁce
BP. For these 6 studies, there was a reduction in mean
SBP and DBP at 6 months of –13.2 mm Hg (95% CI:
–19.4 to –7.0 mm Hg) and –7.3 mm Hg (95% CI: –10.2 to
–4.5 mm Hg), respectively, before compared with after
RDN (p < 0.0001 for SBP and p < 0.00001 for DBP).
Statistical heterogeneity was present for the SBP response
only (I2 ¼ 76% for SBP and 0% for DBP).
Catheter comparison. A total of 5 different catheters
were employed among the 12 studies: the Symplicity/Flex
catheter (Medtronic, Minneapolis, Minnesota) is a radio-
frequency ablation catheter designed for RDN, the Celsius
ThermoCool and Navistar ThermoCool (Biosense Webster
Diamond Bar, California) are irrigated radiofrequency ab-
lation catheters, the Marinr (Medtronic, Minneapolis,
Minnesota) is a standard steerable radiofrequency ablation
catheter, and the PARADISE (ReCor Medical, Ronkon-
koma, New York) is an ultrasound ablation catheter. Given
the overlap of 18 patients between 2 studies with separatetiﬁed by follow-up time among controlled studies following renal sympathetic
Renal Sympathetic Denervation in Patients With Treatment-Resistant Hypertension
Figure 3 Meta-Analysis of Uncontrolled Studies
Forest plot demonstrating the changes in systolic and diastolic blood pressures stratiﬁed by follow-up time among uncontrolled studies following RDN. Symplicity HTN-1 ¼
catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months; other abbreviations as in Figure 2.
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238study designs, we excluded the Symplicity HTN-2 study
(30) from the comparison of catheter meta-analysis and
included the Ukena et al. study (28), given the larger amount
of included patients treated with RDN. With all 95% CI
overlapping, there is no evidence of difference in the ach-
ieved BP response after RDN among the different catheters
used (Fig. 4).Procedural safety. The pooled nonresponder rate was
13.3%. The Kaltenbach et al. (31) study had the highest
nonresponder rate, and excluding this study from the pooled
estimate decreased the nonresponder rate to 11.7%. No
deaths were reported during the stipulated follow-up periods.
A total of 5 procedural complications were reported (<1%).
These included 1 renal artery dissection (remote from where
Figure 4 Catheters Used for RDN
Forest plot, stratiﬁed by catheter type, demonstrating the change in systolic blood pressure at 3-month follow-up after RDN. Testing for heterogeneity between catheter and
blood pressure–lowering effect is represented at the bottom of the ﬁgure using the I2 statistic. Three-month follow-up time was used for comparison of catheters as all
catheters employed had this minimal length of follow-up. Note, Symplicity HTN-2 is not included in this analysis as 18 patients overlapped with the Ukena et al. (30) study, and
this study had a greater number of patients treated with RDN. Abbreviations as in Figures 2 and 3.
JACC Vol. 62, No. 3, 2013 Davis et al.
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239RDN was performed) (16) and 4 pseudoaneurysms at the
site of arterial puncture (16,30,34).
Discussion
We have conducted the ﬁrst systematic review and meta-
analysis of the published body of literature pertaining to
RDN in patients with RH. Our study was designed to
evaluate the effect of RDN on BP reduction in a RH
population. We found that there was a substantial reduction
in BP after RDN at 6 months, which was apparent as early
as 3 months and sustained up to 12 months. Importantly,
the rate of procedural complications was quite low.
We chose to pool the results of the studies based on the
study design. Hence, the 2 randomized controlled trials were
pooled with the only controlled cohort study, and the
uncontrolled observational studies were pooled together.
Observational studies tend to overestimate treatment effectsby confounding by indication. In our analysis, however,
all studies have demonstrated a consistent BP reduction
regardless of study design.
The current study population is composed of only 561
patients, which is a small number for a meta-analysis. It
represents, however, most of the published experience of
RDN in patients with RH. In a meta-analysis, more
important than the number of patients is the number of
included studies, especially when the outcome is continuous.
As RDN is now used for clinical care in Europe, Canada,
and parts of Asia, knowledge of the current extent of effec-
tiveness of the procedure, and the source of the evidence, is of
utmost importance. Before large studies are completed and
reported, the quality of the evidence and effectiveness and
safety of the procedure must be based on current data.
The short-to-intermediate term data suggests that RDN is
safe andwell-tolerated, with themost commonperiprocedural
complaint being abdominal pain that responds to sedatives
Davis et al. JACC Vol. 62, No. 3, 2013
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240and/or narcotics (16,38). Serial vascular imaging follow-up up
to 6 months in the Symplicity HTN-1 (catheter-based renal
sympathetic denervation for resistant hypertension: durability
of blood pressure reduction out to 24 months) trial (34) did
not reveal renal artery abnormalities secondary toRDN (based
on renal duplex, magnetic resonance imaging or computed
tomography angiography). Serial biochemical follow-up did
not demonstrate deterioration in renal function (30,34). The
only complications identiﬁed in our review were pseudoa-
neurysms at the vascular access site in 4 subjects, and 1 case of
renal artery dissection on initial placement of the catheter prior
to delivery of the radiofrequency signal.Hence, the renal artery
dissection was the only non-access-related complication re-
ported. Among the 12 studies included in the meta-analysis,
8 studies presented data on follow-up imaging of the
renal arteries via ultrasound duplex, computed tomography
angiography or magnetic resonance imaging angiography
(16,20,21,30,31,33,34,36). Of the 191 patients with follow-
up imaging, there were no documented cases of renal artery
stenosis, and only 2 patients had progression of previously
visualized renal artery atherosclerosis. To date, 2 case reports
(39,40) have been published of individual patients whose
blood pressure initially responded to RDN but subsequently
had an increase in blood pressure on follow-up visits. In both
instances, renal Doppler and angiography demonstrated renal
artery stenoses, whichwere treated by renal artery stenting. It is
still unclear what proportion of patients develops renovascular
abnormalities following RDN. Further studies are needed to
evaluate long-term changes in renal artery anatomy after RDN
as well as to determine the appropriate imaging follow-up.
The average nonresponder rate, deﬁned as a reduction in
BP of <10 mm Hg after RDN, was 13%. Careful exami-
nation of the studies shows that patients who had a lower
baseline sBP (<150 mm Hg) were less likely to respond to
RDN. The Kaltenbach et al. (31) study included patients
with sBP between 140 and 160 mm Hg and had the highest
nonresponder rate of nearly 50%. Therefore, it appears that
patients with severe elevations of BP may derive the greatest
relative beneﬁt from RDN. It remains unclear if the
response persists in this patient population at long-term
follow-up or if a rebound phenomenon may occur.
In addition to the primary BP-lowering effect, secondary
effects of RDN have been documented. Brant et al. (22)
showed that RDN led to a decrease in left ventricular
hypertrophy, a decrease in end-systolic volume, and an
increase in left ventricular ejection fraction. Mahfoud et al.
(24) showed that RDN led to a signiﬁcant reduction in
fasting blood glucose as well as a reduction in insulin and C-
peptide levels. Additionally, Mahfoud et al. (23) showed
that RDN reduced albuminuria. A recent double-blind
study (36) showed that RDN prevented a recurrence of
atrial ﬁbrillation after pulmonary vein isolation. Another
study (28) showed RDN led to a reduction in heart rate and
prolongation of the PR interval.
We did not identify any studies directly comparing the
effectiveness of different catheters. Based on the studiesincluded in this meta-analysis, the magnitude of the ach-
ieved BP reduction was consistent with all of the different
catheters employed. Although RDN-speciﬁc catheters with
multiple electrodes are being evaluated, it remains to be seen
whether they are more effective at lowering BP.
Current studies. A number of RDN trials are currently
underway. The Symplicity-HTN 3 (Renal Denervation in
Patients With Uncontrolled Hypertension) trial (41)
(NCT01418261) is a single-blind clinical trial that is
randomizing 530 patients in a 2:1 fashion to RDN or control
with a follow-up period of 6 months. The INSPiRED (Renal
Denervation for Management of Drug-Resistant Hyperten-
sion) study (NCT01505010) is a randomized clinical trial with
a longer follow-up period of 36months. TheDEPART (Study
of Catheter Based Renal Denervation Therapy in Hyperten-
sion) (NCT01522430) is a double-blind clinical trial that is
randomizing patients to RDN or sham procedure with
a follow-up period of 6 months. The SymplicityHF (Renal
Denervation in Patients With Chronic Heart Failure and
Renal Impairment Clinical Trial) (NCT01392196) is evalu-
ating the effect of RDN in patients with heart failure, and
contrary to the aforementioned studies that will be focusing on
BP response, this studywill focus on procedural safety and renal
and cardiac function. The DREAMS (Denervation of the
Renal Artery in Metabolic Syndrome) study (NCT01465724)
is evaluating the effect of RDN in patients with metabolic
syndrome, with the primary outcome being a change in insulin-
resistance parameters after 12 months of follow-up.
Study limitations. First, most of the included studies were
observational in nature and thus may be affected by con-
founding by indication and/or selection bias.Whereas the BP
reductionwasmodestly greater in the observational controlled
study than in either of the randomized controlled studies,
large clinically important treatment effects were reported in all
controlled studies. Second, with the use of published aggre-
gate data, we were unable to examine the effect of RDN in
patient subgroups. Third, inclusion was restricted to pub-
lished studies and may therefore be affected by publication
bias. Fourth, the follow-up rate was quite limited in many of
the included studies, resulting in less than 70% 6-month
follow-up. Fifth, although we conducted secondary analyses
that were stratiﬁed by catheter type, there were 5 different
catheters used in the 12 included studies and studies of
catheters other than the Symplicity catheter were of modest
size. Consequently, there were insufﬁcient data to draw
meaningful conclusions regarding the comparative efﬁcacy of
the different catheters. Lastly, given the recent evolution of
RDN, the pooled person-time remains modest.
Conclusions
The current available data suggest that RDN results
in a substantial BP reduction at 6-month follow-up in
patients with RH. With few adverse events reported, avail-
able data also suggest that RDN has a favorable safety
proﬁle. Nonetheless, large randomized controlled trials with
JACC Vol. 62, No. 3, 2013 Davis et al.
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241long-term follow-up are needed to conﬁrm the sustained
efﬁcacy and safety of RDN in this patient population.
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APPENDIX
For bias analysis information, please see the online version of this article.
